labetuzumab govitecan (IMMU-130) - Immunomedics
Immunomedics: Q3 FY 2015 Results (Immunomedics) - May 8, 2015 - Anticipated data from P2 trial (NCT01915472) in metastatic CRC at ASCO 2015 on June 2 
Anticipated P2 data • Colorectal Cancer • Oncology
http://www.immunomedics.com/pdfs/news/2015/pr05062015.pdf
 
May 8, 2015
 
.